Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

for this reason. The overall rate of discontinuation due to adverse events was 16%(1).

About LBH589Because it is an investigational compound, the safety and efficacy profile of LBH589 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of uncertainty of clinical trials, there is no guarantee that LBH589 will ever be commercially available anywhere in the world.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "investigational," "potential," "investigating," "ongoing," "encouraging," "committed," "promising," or similar expressions, or by express or implied discussions regarding potential future approvals to market LBH589, or regarding potential future revenues from LBH589. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that LBH589 will be submitted or approved for sale in any market, or that LBH589 will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)...  Over 100 million adults suffer from chronic pain ... daily. Chronic and acute pain dramatically impacts quality of ... fulfill the need for non-surgical, interventional solutions and medication ... On October 28th, a new pain management center opened ... community.  This new facility boasts cutting edge technologies ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today ... trial of,KW-3902, an adenosine A1 receptor antagonist in ... heart failure (CHF),that indicate a strong trend toward ... KW-3902 experienced a higher rate of,improvement in dyspnea, ...
... Results Presented at the 12th Congress of ... 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... EHA in Vienna, Austria, showed positive responses ...
Cached Medicine Technology:Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
(Date:11/27/2014)... November 27, 2014 “LAB.C” was featured on ... the latest and coolest technology products available to consumers. Mallory ... product review and shared with viewers the company ... and Android devices. , Consumers love portability and functionality. ... Cable Case for the iPhone5 and 5S has a portable ...
(Date:11/27/2014)... HealthPostures, a leading national ... has announced that it has entered into a ... partnership will put HealthPostures' products into central Indiana’s ... addition to having its products sold through Commercial ... products with the business decision makers in the ...
(Date:11/27/2014)... Marietta, GA (PRWEB) November 27, 2014 "The ... the whole month of December is full of laughter as ... Tandy Wilson won by making a sweater from scratch. " ... lit Christmas tree, and if that weren't ridiculous enough, the ... on top. , For those interested in participating this ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 Ethane ... has announced it will provide a 10% Christmas discount on ... month of December. The discount offer will begin on 1 ... 2014. , About this offer, a PPC professional working ... for all, especially for small businesses, as this big discount ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... problem drinkers using alcohol to cope with personal problems ... drinking into adulthood, a recent study suggests. , The ... are still high-risk drinkers by age 34 may have ... development that typically occurs during college, including the ability ...
... 24 Conseco, Inc. (NYSE: CNO ) ... existing $911.8 million senior secured credit agreement. Banc ... in connection with the amendment. The amendment, which ... in the current repayment schedule, is expected to provide ...
... "Hangin, Out With My Baby," ... with their newborns, infants and toddlers, will be distributed free ... hospitals throughout the U.S. Starting today with a live concert ... CDs will be given away this year by participating hospitals.Arranged ...
... Cancer Society Cancer Action Network, the American Heart Association, ... Kids applaud Senator Frank Lautenberg of New Jersey,s call ... authority and immediately remove e-cigarettes from the market. ... publications during the past few weeks saying that e-cigarettes ...
... help metropolitan public health agencies,prepare to deliver essential ... or natural disease outbreak has succeeded in improving,the ... Corporation study. , Researchers found that the federal ... areas, appears to have improved,agencies, ability to rapidly ...
... experts at The University of Nottingham have shown that ... the quality of life for many community-based dialysis patients. ... journal Biomaterials , have shown that the catheter ... wider variety of pathogens and protect Continuous Ambulatory Peritoneal ...
Cached Medicine News:Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 2Health News:Project 'Hangin' Out With My Baby' Launches National Children's Music Giveaway Campaign at California Hospital Medical Center in Los Angeles 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
...
Medicine Products: